고형암 (전체)

434개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved434 programs
AntibodyLimited DatastaleNational University Hospital, S…Phase 1

nivolumab (Opdivo, Oxaliplatin & Nivolumab)

Peritoneal Carcinomatosis · Peritoneal Carcinomatosis

#PeritonealCarcinomatosis#Antibody#Phase1#monoclonal-antibody#National
Trials 1Status Recruiting
ADCLimited DatastaleBioAtla, Inc.Phase 2

Ozuriftamab Vedotin (Ozuriftamab Vedotin)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNingbo Cancer HospitalPhase 2

PD-1 antibody expressing mesothelin specific CAR-T cells (PD-1 antibody expressing mesothelin specific CAR-T cells)

Solid Tumor, Adult; Advanced Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleMerckPhase 3

pembrolizumab (Keytruda, PD-1 mAb, Pembrolizumab/Finotonlimab, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#monoclonal-antibody#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Recruiting
AntibodyLimited DatastaleZhongda HospitalPreclinical

PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab)

Hepatocellular Carcinoma · PD-1

#PD-1#Antibody#Preclinical#monoclonal-antibody#HepatocellularCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastalePfizerPhase 1

nivolumab (Opdivo, TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Nivolumab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastalePfizerPhase 1

PF-07901800 (TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Rituximab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
CGTLimited DatastalePrecigen, IncPhase 1

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

PVE+cTACE+Camrelizumab+Apatinib (PVE+cTACE+Camrelizumab+Apatinib)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, PXS-5505 and Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma; Cancer of Liver · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#CancerofLiver+1
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Pan-T booster co-expressing MSLN CAR T cell (Pan-T booster co-expressing MSLN CAR T cell)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
ADCLimited DatastaleMerckPhase 2

PEV (Pembrolizumab & Enfortumab Vedotin, Pembrolizumab & Enfortumab Vedotin (PEV))

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#antibody-drug-conjugate#Merck
Trials 1Status Recruiting
ADCLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Enfortumab Vedotin)

Bellini Carcinoma; Collecting Duct Carcinoma · Bellini Carcinoma

#BelliniCarcinoma#ADC#Phase2#antibody-drug-conjugate#CollectingDuctCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleDana-Farber Cancer InstitutePhase 2

Pembroluzimab (Pembroluzimab)

HPV-positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma · HPV-positive Oropharyngeal Squamous Cell

#HPV-positiveOropharyngealSquamou#Antibody#Phase2#monoclonal-antibody#OropharyngealSquamousCellCarcino+1
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 2

durvalumab (Imfinzi, Pemigatinib and Durvalumab)

Biliary Tract Carcinoma; Cholangiocarcinoma · Biliary Tract Carcinoma

#BiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Cholangiocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 3

Petosemtamab (Petosemtamab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Merus
Trials 1Status Recruiting
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued

17 / 22 pages

← PreviousNext →